13F-HR/A: J&J Amends Q3 2025 Holdings, Discloses $504M Portfolio

Johnson & Johnson filed an amended 13F report, restating its institutional investment holdings totaling over $503 million for the quarter ended September 30, 2025.

Summary

• Johnson & Johnson filed an amended Form 13F-HR, Amendment Number 1, which is a restatement of its previous filing.
• The report covers the calendar quarter ended September 30, 2025.
• The total value of the institutional investment manager's holdings is $503,922,707.
• The filing lists 20 distinct equity holdings across various companies.
• Johnson & Johnson Innovation JJDC, Inc. is included as another manager in this report, contributing to the disclosed holdings.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a neutral to slightly positive disclosure, primarily due to the transparency it provides into J&J's investment activities, despite being a restatement.

Positives

• Provides transparency into Johnson & Johnson's institutional equity investments.
• Includes holdings from Johnson & Johnson Innovation JJDC, Inc., offering a broader view of the company's investment activities.

Negatives

• The need for an amendment (restatement) suggests a prior error or update was required in the initial filing.

Future Outlook

NA

Management Comments

• The person signing the report is authorized to submit it, that all information contained herein is true, correct and complete, and that it is understood that all required items, statements, schedules, lists, and tables, are considered integral parts of this form.

Industry Context

StockSavvy.ai notes that 13F filings provide transparency into the investment strategies of large institutional managers like Johnson & Johnson, offering insights into their portfolio allocations within the healthcare and biotech sectors, which is consistent with J&J's core business.

Comparison to Industry Standards

• The filing adheres to SEC Form 13F requirements, which is standard for institutional investment managers with over $100 million in qualifying assets.
• The disclosure of 20 distinct equity holdings is typical for a diversified institutional portfolio.

Stakeholder Impact

• Shareholders: Provides transparency into the company's investment portfolio, which can inform investment decisions.
• Regulatory Authorities: Fulfills mandated disclosure requirements, ensuring compliance.

Key Dates

Keywords

Johnson & Johnson, 13F, institutional holdings, equity investments, portfolio disclosure, SEC filing, Q3 2025, JJDC